Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30202377 | 1.00 | ENPP2 (0.49) | ENPP2HDAC6 | |
| Hydrochloric Acid SCHEMBL1921111 | 0.99 | ENPP2 (0.49) | ENPP2HDAC6 | |
| SCHEMBL3056004 | 0.96 | ENPP2 (0.47) | ENPP2HDAC6 | |
| SCHEMBL1921277 | 0.89 | HDAC6 (0.51) | ENPP2HDAC6 | |
| SCHEMBL18130455 | 0.84 | ENPP2 (0.67) | ENPP2 | |
| SCHEMBL1919522 | 0.79 | ENPP2 (0.44) | ENPP2 | |
| SCHEMBL1920629 | 0.79 | CYP3A4 (0.45) | — | |
| SCHEMBL1919429 | 0.76 | ENPP2 (0.55) | ENPP2 | |
| SCHEMBL25067211 | 0.75 | ENPP2 (0.55) | ENPP2 | |
| SCHEMBL10085099 | 0.75 | HDAC6 (0.61) | HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 144 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2488195-A2 | NEUROPEPTIDE-2 RECEPTOR (Y-2R) AGONISTS | F. Hoffmann-La Roche AG (CH) | 2012-08-22 | — | — | EP | claimed |
| EP-1962959-B1 | NEUROPEPTIDE-2 RECEPTOR-AGONISTS | HOFFMANN LA ROCHE (CH) | 2012-03-14 | — | — | EP | claimed |
| JP-4836455-B2 | — | — | 2011-12-14 | — | — | JP | claimed |
| CN-102167728-A | Improved gastrin releasing peptide compounds | BRACCO IMAGING SPA | 2011-08-31 | — | — | CN | claimed |
| EP-2352511-A2 | NEUROPEPTIDE-2-RECEPTOR (Y-2R) AGONISTS AND USES THEREOF | F. Hoffmann-La Roche AG (CH) | 2011-08-10 | — | — | EP | claimed |
| US-20110172147-A1 | NEUROPEPTIDE-2 RECEPTOR (Y-2R) AGONISTS | CONDE-KNAPE KARIN | 2011-07-14 | — | — | US | claimed |
| WO-2011045232-A2 | NEUROPEPTIDE-2 RECEPTOR (Y-2R) AGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2011-04-21 | — | — | WO | claimed |
| US-7922998-B2 | bombesin, derivatives and/or analogues capable of complexing metal ions, radionuclides or optical labels, for use in radiotherapy | BRACCO IMAGING S.P.A. (IT) | 2011-04-12 | — | — | US | claimed |
| US-7850947-B2 | Gastrin releasing peptide compounds | BRACCO IMAGING S.P.A. (IT) | 2010-12-14 | — | — | US | claimed |
| US-20100179093-A1 | Neoropeptide-2-Receptor (Y-2R) Agonists | DANHO WALEED | 2010-07-15 | — | — | US | claimed |
| WO-2007065808-A2 | NEUROPEPTIDE-2 RECEPTOR-AGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2007-06-14 | — | — | WO | claimed |
| WO-2007002500-A1 | GASTRIN RELEASING PEPTIDE COMPOUNDS | BRACCO IMAGING S.P.A. (IT) | 2007-01-04 | — | — | WO | claimed |
| US-20060239914-A1 | Gastrin releasing peptide compounds | BRACCO IMAGING S.P.A. (IT) | 2006-10-26 | — | — | US | claimed |
| US-20060239923-A1 | Gastrin releasing peptide compounds | BRACCO IMAGING S.P.A. (IT) | 2006-10-26 | — | — | US | claimed |
| CN-1738650-A | Improved gastrin releasing peptide compounds | BRACCO IMAGING SPA (IT) | 2006-02-22 | — | — | CN | claimed |
| US-20060018830-A1 | Gastrin releasing peptide compounds | BRACCO IMAGING S.P.A. (IT) | 2006-01-26 | — | — | US | claimed |
| EP-1585549-A2 | IMPROVED GASTRIN RELEASING PEPTIDE COMPOUNDS | Bracco Imaging S.p.A. (IT) | 2005-10-19 | — | — | EP | claimed |
| US-20040253225-A1 | bombesin, derivatives and/or analogues capable of complexing metal ions, radionuclides or optical labels, for use in radiotherapy | BRACCO IMAGING S.P.A. (IT) | 2004-12-16 | — | — | US | claimed |
| WO-2004065407-A2 | IMPROVED GASTRIN RELEASING PEPTIDE COMPOUNDS | BRACCO IMAGING S.P.A. (IT) | 2004-08-05 | — | — | WO | claimed |
| US-20040136906-A1 | Gastrin releasing peptide compounds | BRACCO IMAGING S.P.A. (IT) | 2004-07-15 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060239914-A1 | Gastrin releasing peptide compounds | GRPR, GIPR, CCKBR | ENPP2 708/4885HDAC6 3706/4885 |
| US-20100179093-A1 | Neoropeptide-2-Receptor (Y-2R) Agonists | NPY2R, NPY1R, NPY4R | ENPP2 315/4885HDAC6 2928/4885 |
| US-20110172147-A1 | NEUROPEPTIDE-2 RECEPTOR (Y-2R) AGONISTS | NPY2R, NPY1R, NPY4R | ENPP2 233/4885HDAC6 2104/4885 |
| US-20040253225-A1 | bombesin, derivatives and/or analogues capable of complexing metal ions, radionuclides or optical labels, for use in radiotherapy | GRPR, MLNR, NPBWR1 | ENPP2 550/4885HDAC6 2653/4885 |
| US-20060239923-A1 | Gastrin releasing peptide compounds | GRPR, GIPR, CCKBR | ENPP2 443/4885HDAC6 3691/4885 |
| US-20060018830-A1 | Gastrin releasing peptide compounds | GRPR, GIPR, CCKBR | ENPP2 708/4885HDAC6 3706/4885 |
| US-20040136906-A1 | Gastrin releasing peptide compounds | GRPR, GIPR, MLNR | ENPP2 574/4885HDAC6 3052/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.